Why Santarus Inc. Shares Soared

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Santarus (NASDAQ: SNTS  ) surged nearly 40% today after fellow biotech Salix Pharmaceuticals (NASDAQ: SLXP  ) agreed to acquire it for about $2.6 billion.

So what: The all-cash deal values Santarus at $32 per share and represents a 37% premium to its closing price on Thursday. Salix is making the move to strengthen its leadership position in the gastroenterology drug market, and judging by its own stock's 16% pop today, Mr. Market is thrilled with the price that management is paying to do it.

Now what: Salix expects Santarus to be immediately and significantly accretive to earnings.

"We are very pleased to be able to merge our sales forces, combine two complementary product portfolios, expand our pipeline, diversify revenue, access health care providers in primary care, add a significant number of health care prescribers to our called-on universe and to better position Salix for success in the present as well as the future," said Salix CEO Carolyn Logan.

So while Santarus' upside is limited at this point, Salix's newly bolstered scale might be worth looking into. 

Another big growth stock to consider
This incredible tech stock is growing twice as fast as Google and Facebook, and more than three times as fast as Amazon.com and Apple. Watch our jaw-dropping investor alert video today to find out why The Motley Fool's chief technology officer is putting $117,238 of his own money on the table, and why he's so confident this will be a huge winner in 2013 and beyond. Just click here to watch!


Read/Post Comments (2) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On November 26, 2013, at 10:22 AM, FastGrowth wrote:

    I own Santarus and am new to trading on the Nasdaq.

    What happens to my Santarus shares now that Salix purchased the company?

    Will Salix take over my shares and re-imburse me sometime next year?

    If yes, when will this happen?

    and, if it does happen, whats the point of still hanging on to my Santarus shares?

  • Report this Comment On January 08, 2014, at 12:23 AM, terrier wrote:

    I did not take up the offer of $32 dollars a share for my SNTS because I was travelling. So is my SNTS account a dud, or can I sell it, or does it transfer to now be under the name Salix Pharma ? Right now it looks like a $000 account.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2719072, ~/Articles/ArticleHandler.aspx, 8/31/2014 6:26:36 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement